Cancer Family
Malignant Histiocytic and Dendritic Cell Neoplasm
CI-CAN-00000237Explore in graph →
Hematologic43 active trials1 approved drugs2 evidence items
- NCIt
- C212210
Loading cancer entity…
Cancer Family
CI-CAN-00000237Explore in graph →
Clinical trials
82 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (9)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07785180 | A Non-interventional Study of Participants With BPDCN Treated With Chemotherapy | recruiting | — | 140 | Stemline Therapeutics, Inc.INDUSTRY | 11 | Sep 15, 2026 | clinicaltrials |
| NCT04216524 | Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm | recruiting | Phase 2 | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT06690827 | Clinical Trial of CD123-targeted CAR-NK Therapy for Relapse/Refractory AML or BPDCN | recruiting | Phase 1 | 30 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Aug 28, 2026 | clinicaltrials |
| NCT07785154 | A Registry-study of ELZONRIS in Participants With BPDCN | recruiting | — | 80 | Stemline Therapeutics, Inc.INDUSTRY | 4 | Aug 25, 2026 | clinicaltrials |
| NCT07778212 | Orelabrutinib Combined With Pola-R-CHP as First-Line Treatment for Patients With Intermediate- to High-Risk DLBCL | recruiting | N/A | 30 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT07570823 | A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma | recruiting | Phase 3 | 101 | Sinocelltech Ltd.INDUSTRY | 1 | Aug 13, 2026 | clinicaltrials |
| NCT07749365 | Hypofractionated Radiotherapy Plus GM-CSF, Pomalidomide and Glofitamab for Newly Diagnosed PCNS-DLBCL | recruiting | Phase 2 | 53 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT06013423 | Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases | recruiting | Phase 2 | 54 | Fred Hutchinson Cancer CenterOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT07680933 | Orelabrutinib Combined With Standard Immunochemotherapy With or Without Autologous Hematopoietic Stem Cell Transplantation (Auto-HSCT) for Newly Diagnosed Diffuse Large B-cell Lymphoma (DLBCL) | recruiting | Phase 2 | 30 | The Affiliated Hospital of Xuzhou Medical UniversityOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT07007052 | Phase II Study Evaluating the Efficacy and Safety of the Combination of Tagraxofusp and Venetoclax in Treatment-naive Blastic Plasmacytoid Dendritic Cell Neoplasm Patients(TAGVEN) | recruiting | Phase 2 | 33 | French Innovative Leukemia OrganisationOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT03113643 | SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | recruiting | Phase 1 | 72 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT05430971 | Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International Registry | recruiting | — | 200 | Immune Oncology Research InstituteOTHER | 15 | Jun 5, 2026 | clinicaltrials |
| NCT04318678 | CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML) | recruiting | Phase 1 | 108 | St. Jude Children's Research HospitalOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT03326921 | HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant | recruiting | Phase 1 | 24 | Fred Hutchinson Cancer CenterOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT06481826 | Glofitamab in Chinese Patients With R/R DLBCL | recruiting | — | 20 | Peking Union Medical College HospitalOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT07288879 | DALY II Japan/MB-CART2019.1 for DLBCL(DALY II Japan) | recruiting | Phase 2 | 31 | Miltenyi Biomedicine GmbHINDUSTRY | 1 | Jan 8, 2026 | clinicaltrials |
| NCT05950802 | Optimizing lymphoDepletion to Improve Outcomes In Patients Receiving Cell Therapy With Yescarta(ODIN) | recruiting | Phase 1 | 40 | University Health Network, TorontoOTHER | 1 | Dec 8, 2025 | clinicaltrials |
| NCT07255963 | Pirtobrutinib, Lisaftoclax, and Rituximab in the Treatment of R/R DLBCL | recruiting | Phase 2 | 29 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Dec 1, 2025 | clinicaltrials |
| NCT06712810 | Q702 for the Treatment of Patients With Hematologic Malignancies | recruiting | Phase 1 | 46 | Mayo ClinicOTHER | 1 | Oct 10, 2025 | clinicaltrials |
| NCT04079179 | Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders(NACHO-COBI) | recruiting | Phase 2 | 90 | Carl AllenOTHER | 1 | Sep 18, 2025 | clinicaltrials |
| NCT07057765 | Predictive Value of CRP, Albumin, CAR, and mGPS in Treatment Outcomes of DLBCL | recruiting | — | 40 | Ain Shams UniversityOTHER | 1 | Jul 10, 2025 | clinicaltrials |
| NCT06891157 | Chidamide Plus R-CHOP in Newly Diagnosed Double-Expressor Diffuse Large B-Cell Lymphoma With Other Molecular Subtypes | recruiting | Phase 2 | 148 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Mar 24, 2025 | clinicaltrials |
| NCT06151080 | Lenalidomide Combined With G-CHOP in the Treatment of Newly Diagnosed DLBCL With FL | recruiting | Phase 2 | 38 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Feb 19, 2025 | clinicaltrials |
| NCT06158399 | AZA Combined With RCHOP in P53-mutated DLBCL. | recruiting | Phase 2 | 52 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Feb 19, 2025 | clinicaltrials |
| NCT06026488 | Real-World Study of DLBCL With Different Genetic Subtypes | recruiting | — | 10,000 | Ruijin HospitalOTHER | 1 | Dec 19, 2024 | clinicaltrials |
| NCT05476770 | Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies | recruiting | Phase 1 | 54 | Therapeutic Advances in Childhood Leukemia ConsortiumOTHER | 2 | Dec 6, 2024 | clinicaltrials |
| NCT05641428 | Comparison of Point-of-care Produced CAR T-cell with Commercial CAR T-cells in Patients with R/R LBCL(HOVON161) | recruiting | Phase 2 | 300 | University Medical Center GroningenOTHER | 1 | Sep 23, 2024 | clinicaltrials |
| NCT06526065 | Molecular Mechanisms in Malignant Lymphoma- Predict (MMML Predict) | recruiting | — | 500 | University Medical Center GoettingenOTHER | 1 | Jul 29, 2024 | clinicaltrials |
| NCT06299553 | Study to Evaluate the Effectiveness of Tafasitamab in Combination With Lenalidomide Followed by Tafasitamab Monotherapy in Relapsed or Refractory Diffuse Large B-cell Lymphoma Non-transplant Eligible Patients in Italy (PRO-MIND) | recruiting | — | 200 | Incyte Biosciences Italy S.r.lINDUSTRY | 1 | May 22, 2024 | clinicaltrials |
Data updated 15 days agoSource updated Sep 15, 2026source: clinicaltrials